Novo Nordisk (NOVO) M&A announcement summary

Deal rationale and strategic fit

• Acquisition is the largest R&D-related deal in company history, expanding the portfolio in diabetes, obesity, and MASH, a major comorbidity with high unmet need, and aligns with the long-term strategy to address these areas.

• Efruxifermin (EFX), Akero’s late-stage asset, is a strong scientific and strategic fit, complementing existing expertise and potentially serving as a cornerstone or combination therapy for MASH.

• Patient overlap between core therapy areas and MASH supports the strategic fit and expands the addressable patient population.

• The deal aims to position the company as a leader in innovative medicines for metabolic diseases, leveraging expertise in obesity-related comorbidities.

• Addresses significant unmet need in MASH, especially for patients with advanced fibrosis (F4/cirrhosis).

Financial terms and conditions

• Acquisition valued at $4.7 billion at closing, with an additional $0.5 billion contingent value right (CVR) of $6 per share upon US regulatory approval for EFX in compensated cirrhosis.

• Purchase price is $54 per share in cash; transaction unanimously approved by Akero's Board and expected to close around year-end, subject to regulatory approvals.

• Mainly debt financed; not expected to impact 2025 operating profit outlook but will reduce 2025 free cash flow by ~$4 billion.

• The acquisition is expected to have a -3% impact on operating profit growth in 2026 due to increased R&D costs for phase III trials.

• No significant change in operating profit outlook for 2025; minor transition costs may occur in Q4.

Synergies and expected cost savings

• Efruxifermin’s development will leverage existing expertise in GLP-1 and metabolic disease, with potential for combination therapies and portfolio integration.

• EFX’s holistic profile may address multiple risk factors, including cardiovascular disease, enhancing portfolio value.

• Novo Nordisk’s scale and expertise expected to unlock EFX’s full potential and reach more patients.

• No additional CapEx expected for manufacturing EFX, as external partners and CMOs will be used.